Profile data is unavailable for this security.
About the company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
- Revenue in USD (TTM)132.10m
- Net income in USD-80.95m
- Incorporated1987
- Employees126.00
- LocationHeron Therapeutics Inc4242 Campus Point Court, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 251-4400
- Websitehttps://www.herontx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics Inc | 2.51m | -99.43m | 379.14m | 76.00 | -- | 1.77 | -- | 151.05 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| AC Immune SA | 16.38m | -60.40m | 383.90m | 133.00 | -- | 2.40 | -- | 23.44 | -0.6773 | -0.6773 | 0.1843 | 1.61 | 0.088 | -- | 61.04 | 123,144.50 | -32.45 | -18.25 | -35.04 | -19.52 | -- | -- | -368.77 | -148.29 | -- | -- | 0.0225 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 384.96m | 224.00 | -- | 0.6382 | -- | 5,661.15 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -115.28m | 397.05m | 33.00 | -- | 1.63 | -- | -- | -4.70 | -4.70 | 0.00 | 5.50 | 0.00 | -- | -- | 0.00 | -76.12 | -- | -82.46 | -- | -- | -- | -- | -- | -- | -2.15 | 0.0856 | -- | -- | -- | -260.87 | -- | -- | -- |
| Grail Inc | 100.18m | -1.49bn | 399.58m | 1.36k | -- | 0.1069 | -- | 3.99 | -56.16 | -56.16 | 3.77 | 140.84 | -- | -- | -- | 74,763.43 | -- | -47.45 | -- | -48.55 | 41.91 | -- | -1,488.21 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -129.44m | 407.55m | 186.00 | -- | 1.57 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| ACELYRIN Inc | 0.00 | -240.16m | 407.99m | 130.00 | -- | 0.6324 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Heron Therapeutics Inc | 132.10m | -80.95m | 412.79m | 126.00 | -- | -- | -- | 3.12 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 412.85m | 162.00 | -- | 1.21 | 271.97 | 3.47 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Ocugen Inc | 7.05m | -58.50m | 414.34m | 65.00 | -- | 13.69 | -- | 58.77 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Alector Inc | 96.41m | -120.61m | 418.31m | 244.00 | -- | 2.34 | -- | 4.34 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Verve Therapeutics Inc | 16.05m | -196.83m | 419.83m | 255.00 | -- | 0.7188 | -- | 26.16 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| OmniAB Inc | 21.05m | -63.48m | 431.65m | 106.00 | -- | 1.43 | -- | 20.51 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Terns Pharmaceuticals Inc | 0.00 | -91.06m | 434.63m | 66.00 | -- | 1.84 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 434.98m | 52.00 | -- | 7.50 | -- | 30.73 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Exscientia PLC (ADR) | 24.87m | -164.04m | 442.26m | 483.00 | -- | 1.54 | -- | 17.78 | -1.30 | -1.30 | 0.1968 | 3.32 | 0.0364 | -- | 34.98 | 51,492.63 | -24.02 | -- | -27.31 | -- | -34.40 | -- | -659.56 | -- | -- | -- | 0.0556 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
Data as of Jul 03 2024. Currency figures normalised to Heron Therapeutics Inc's reporting currency: US Dollar USD
47.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 31 Mar 2024 | 26.71m | 17.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.89m | 5.24% |
| Velan Capital Investment Management LPas of 31 Mar 2024 | 6.99m | 4.64% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.72m | 4.46% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 6.33m | 4.20% |
| Tejara Capital Ltd.as of 31 Mar 2024 | 4.41m | 2.93% |
| Palisade Capital Management LPas of 31 Mar 2024 | 3.73m | 2.48% |
| Millennium Management LLCas of 31 Mar 2024 | 3.17m | 2.10% |
| Adage Capital Management LPas of 31 Mar 2024 | 2.91m | 1.93% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.80m | 1.86% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
